Elective nodal radiotherapy in prostate cancer
G De Meerleer, C Berghen, A Briganti… - The Lancet …, 2021 - thelancet.com
In patients with prostate cancer who have a high risk of pelvic nodal disease, the use of
elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled …
elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled …
Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate-and high-risk prostate cancer: early oncological outcomes from a …
JFP Lestingi, GB Guglielmetti, QD Trinh, RF Coelho… - European urology, 2021 - Elsevier
Background The role of extended pelvic lymph node dissection (EPLND) in the surgical
management of prostate cancer (PCa) patients remains controversial, mainly because of a …
management of prostate cancer (PCa) patients remains controversial, mainly because of a …
Radiotherapy of oligometastatic prostate cancer: a systematic review
P Rogowski, M Roach, NS Schmidt-Hegemann… - Radiation …, 2021 - Springer
Background Due to improved imaging sensitivity, the term “oligometastatic” prostate cancer
disease is diagnosed more often, leading to an increasing interest in metastasis-directed …
disease is diagnosed more often, leading to an increasing interest in metastasis-directed …
Robot-assisted prostate-specific membrane antigen–radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective …
HA de Barros, MN van Oosterom, ML Donswijk… - European Urology, 2022 - Elsevier
Background It has been proven that intraoperative prostate-specific membrane antigen
(PSMA)-targeted radioguidance is valuable for the detection of prostate cancer (PCa) …
(PSMA)-targeted radioguidance is valuable for the detection of prostate cancer (PCa) …
Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study
BM Privé, SMB Peters, CHJ Muselaers, IM van Oort… - Clinical Cancer …, 2021 - AACR
Abstract Purpose:[177Lu] Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be …
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be …
Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought
Background Long-term outcomes of patients treated with salvage lymph node dissection
(sLND) for nodal recurrence of prostate cancer (PCa) remain unknown. Objective To …
(sLND) for nodal recurrence of prostate cancer (PCa) remain unknown. Objective To …
Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body …
Background Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT)
are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer …
are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer …
PEACE V–Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): A study protocol for a randomized controlled phase II trial
A De Bruycker, A Spiessens, P Dirix, N Koutsouvelis… - BMC cancer, 2020 - Springer
Background Pelvic nodal recurrences are being increasingly diagnosed with the
introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the …
introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the …
Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable …
T Horn, M Krönke, I Rauscher, B Haller, S Robu… - European urology, 2019 - Elsevier
Background Prostate-specific membrane antigen (PSMA)-ligand positron emission
tomography (PET) allows detection of metastatic prostate cancer (PC) lesions at low prostate …
tomography (PET) allows detection of metastatic prostate cancer (PC) lesions at low prostate …
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
BM Privé, MJR Janssen, IM Van Oort, CHJ Muselaers… - BMC cancer, 2020 - Springer
Background In recent years, there is increasing evidence showing a beneficial outcome (eg
progression free survival; PFS) after metastases-directed therapy (MDT) with external beam …
progression free survival; PFS) after metastases-directed therapy (MDT) with external beam …